EyeGate Pharmaceuticals, Inc. logo
EyeGate Pharmaceuticals, Inc. EYEG

EyeGate Pharmaceuticals, Inc. Balance Sheet 2011-2026 | EYEG

Annual Balance Sheet EyeGate Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-824 K -3.69 M -8 M -7.79 M -3.61 M -8.39 M 3.04 M 1.53 M -1.94 M -

Long Term Debt

278 K - - - - - - - - -

Total Non Current Liabilities

6.39 M 2.08 M 1.48 M 1.4 M 2.75 M - 36.4 M 36.4 M 36.4 M -

Total Current Liabilities

1.77 M 1.41 M 3.86 M 14.8 M 7.31 M 3.42 M 5.02 M 2.57 M 747 K -

Total Liabilities

8.16 M 3.49 M 5.34 M 16.2 M 10.1 M 3.42 M 41.4 M 39 M 37.2 M -

Deferred Revenue

- - 2.69 M 12.3 M 4.22 M 1.91 M - - - -

Retained Earnings

-108 M -100 M -93.2 M -91.8 M -78.6 M -65.3 M -56.9 M -55.1 M -51.2 M -

Total Assets

15.2 M 10.1 M 14.3 M 14.3 M 9.73 M 9.51 M 1.41 M 692 K 2.34 M -

All numbers in USD currency

Balance Sheet is a fundamental financial report of EyeGate Pharmaceuticals, Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.38 -3.64 % $ 131 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alector Alector
ALEC
$ 2.1 -13.79 % $ 216 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Altimmune Altimmune
ALT
$ 4.2 -2.67 % $ 298 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.61 -1.67 % $ 2.6 B usaUSA
Agenus Agenus
AGEN
$ 3.33 - $ 1.19 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 28.87 -4.5 % $ 1.67 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA